---
title: Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function
nct_id: NCT00779922
overall_status: COMPLETED
phase: PHASE2
sponsor: Poitiers University Hospital
study_type: INTERVENTIONAL
primary_condition: Multiple Myeloma
countries: France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00779922.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00779922"
ct_last_update_post_date: 2016-10-11
last_seen_at: "2026-05-12T06:23:44.014Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function

**NCT ID:** [NCT00779922](https://clinicaltrials.gov/study/NCT00779922)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 39
- **Lead Sponsor:** Poitiers University Hospital
- **Conditions:** Multiple Myeloma, Impaired Renal Function
- **Start Date:** 2008-11
- **CT.gov Last Update:** 2016-10-11

## Brief Summary

The purpose of this study is to determine the pharmacokinetic profile of Revlimid® in patients presenting with Multiple Myeloma and impaired renal function, the safety of Revlimid® in the enrolled patients population.

and evaluate the efficacy of Revlimid®-Dexamethasone combination in patients presenting MM and impaired renal function at completion of 3 cycles of treatment.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Documented diagnosis of relapsed or refractory multiple myeloma (MM).
* Age \> 18 years at the time of signing the informed consent form
* Stable renal function

Exclusion Criteria:

* Documented amyloidosis
* Any prior use of Revlimid ®
* Any contraindication to Revlimid ® and especially:
* Lack of acceptable method of birth control for female of childbearing potential (FCPB)

  * Men who don't agree to use condom during the study and 4 weeks after the last study drug intake if their partner is a FCPB.
  * Pregnant or breast feeding women
```

## Arms

- **group 1 to 5** (EXPERIMENTAL)

## Interventions

- **lenalidomide** (DRUG)

## Locations (1)

- Poitiers University Hospital, Poitiers, France

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.poitiers university hospital|poitiers||france` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00779922.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00779922*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*